Suraksha Diagnostic Limited has informed the Exchange about an Update on the Acquisition
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic Limited has completed signing of all definitive agreements to acquire a 63% stake in Fetomat Wellness Private Limited for an amount not exceeding ₹5.19 crore in cash. Fetomat is a Kolkata-based network of fertility and pregnancy care clinics specialising in fetal and maternal medicine, with a FY24 turnover of approximately ₹4.11 crore and EBITDA of around ₹0.56 crore. The deal includes subscription for 16.17% via new shares and purchase of 46.83% from existing shareholders, totalling 3,73,423 equity shares. Post-acquisition, Fetomat will become a subsidiary of Suraksha. The payment of consideration and transfer of shares will be communicated in due course, with completion expected within three months from the original 27 March 2025 board approval.
This is a small-ticket strategic acquisition (₹5.19 crore) that expands Suraksha's service portfolio into fetal medicine and women's health, making Fetomat a subsidiary. The move strengthens its healthcare footprint in eastern India and adds a complementary vertical, though the financial impact is limited given the modest size of the target.